TScan Therapeutics hangs around $1.08; eyes on next week
TScan Therapeutics shares closed at $1.08 Friday after light trading in a shortened week. Shareholders approved doubling authorized voting common shares to 600 million, according to a May 22 filing. The company reported a first-quarter net loss of $28.7 million and held $128.1 million in cash at March 31. Investors await second-quarter ALLOHA trial data and the planned Phase 3 start for TSC-101.